Mizuho Securities Remains a Buy on Atara Biotherapeutics (ATRA)

By Carrie Williams

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics (ATRAResearch Report), with a price target of $43. The company’s shares closed last Monday at $15.62, close to its 52-week low of $11.89.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -4.0% and a 49.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Neon Therapeutics Inc, and Coherus Biosciences.

Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $44.

See today’s analyst top recommended stocks >>

The company has a one-year high of $43.95 and a one-year low of $11.89. Currently, Atara Biotherapeutics has an average volume of 779.7K.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATRA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.